Stocks Basic materials PURE
OTC · Basic materialsPure Bioscience, Inc. (PURE)
Pure Bioscience, Inc. brought in $2.4M of revenue over the twelve months to April 30, 2026, up 26.7% from a year earlier. It posted a net loss of $2.2M. At April 30, 2026 it held $983K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on June 15, 2026.
Watch PURE in 60 secondsWhat Pure Bioscience, Inc. does
Pure Bioscience, Inc. is registered with the SEC under industry code SIC 2890 (Miscellaneous Chemical Products). Its shares trade on OTC under the ticker PURE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.2M | -$2.4M | -$0.02 | n/a |
| 2024 | $2M | -$3.4M | -$0.03 | n/a |
| 2023 | $1.9M | -$4M | -$0.04 | -$3.3M |
| 2022 | $1.9M | -$3.5M | -$0.04 | -$2.5M |
| 2021 | $3.9M | -$2.3M | -$0.03 | -$1.7M |
| 2020 | $6.9M | $4K | $0.00 | $611K |
Full financial statements: income, balance sheet and cash flow
Where PURE ranks in Basic materials
Latest SEC filings
What Pure Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- June 15, 2026Quarterly report 10-Q · period to April 30, 2026Revenue rose 3.1% to $506K versus the same quarter last year; diluted EPS -$0.01 versus -$0.01.
- June 15, 2026
- May 5, 2026
- March 17, 2026Quarterly report 10-Q · period to January 31, 2026Revenue rose 14% to $444K versus the same quarter last year; diluted EPS -$0.01 versus -$0.01.
- March 17, 2026
- February 20, 2026
- December 30, 2025Proxy statement DEF 14A
- December 18, 2025Preliminary proxy statement PRE 14A
- December 15, 2025Quarterly report 10-Q · period to October 31, 2025Revenue rose 27% to $708K versus the same quarter last year; diluted EPS $0.00 versus -$0.01.
- December 15, 2025
Questions about PURE
What does Pure Bioscience, Inc. do?
Pure Bioscience, Inc. is registered with the SEC under industry code SIC 2890 (Miscellaneous Chemical Products). Its shares trade on OTC under the ticker PURE.
Is Pure Bioscience, Inc. profitable?
No. Over the twelve months to April 30, 2026 it reported a net loss of $2.2M on revenue of $2.4M.
How much revenue does Pure Bioscience, Inc. make?
Over the twelve months to April 30, 2026 Pure Bioscience, Inc. reported revenue of $2.4M. That is 26.7% more than a year earlier.
When did Pure Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on June 15, 2026. It covers the period to April 30, 2026.
Similar companies
Compare PURE with
Follow PURE
Get an email when Pure Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PURE: get an email when it filesWhere the numbers come from
Financial figures are the values Pure Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.